Revenue Growth and Profitable Third Quarter
21 February 2025
Revenue Growth and Profitable Third Quarter
For the third quarter ending 31 December 2024, Blis Technologies Limited (BLIS) delivered revenue
of $3.2m, being growth of 4% on the same period last year and a positive EBITDA result of $0.3m
(unaudited).
The nine months to 31 December 2024 saw revenue growth of 17% on the same period last year.
This revenue growth has predominantly come from a $0.9m (34%) increase in B2C revenue across
the Daigou, Amazon and webstore channels, with B2B channel delivering growth of $0.5m (8%)
growth.
“While the B2B channel remains the core pillar of the BLIS business, our B2C focus has been on
increasing profitability in existing channels. BLIS’ will continue to focus on winning in the right
markets with key business partners. This will allow us to leverage the increased consumer awareness
of the importance of maintaining a healthy oral microbiome for overall good health and wellbeing
and is driving them to seek out BLIS’ clinically proven probiotic solutions.” said Scott Johnson, CEO.
Based on the latest customer sales forecasts and market feedback, guidance is for full year revenue
to be in excess of $12m, with EBITDA in the range of $0.6m to $0.8m. This is a pleasing result given
the current tough economic environment and reinforces our commitment to delivering sustainable
profitability.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BGP — Briscoe Group Limited: Full Year Results to 26 January 20252025-03-11
“Results announcement Results for announcement to the market Name of issuer BRISCOE GROUP LIMITED Reporting Period Full Year (52 weeks) – 29 January 2024 to 26 January 2025 Previous Reporting Period Full Year (52 weeks) – 30 January 2023 to 28 January 2024 Currency…”
- PEB — Pacific Edge Limited: Financial Results for the Half Year to 30 September 20242024-11-25
“26 November 2024 AUDITED FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2024 MEDICARE COVERAGE CATALYSTS IN FOCUS DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces steady financial performance for the six months to the…”
- PEB — Pacific Edge Limited: Pacific Edge Releases Quarterly Volumes for Q3 FY252025-01-21
“For more information: Investors: Media: Dr Peter Meintjes Richard Inder Chief Executive The Project Pacific Edge P: +64 21 645 643 P: 022 032 1263 OVERVIEW Pacific Edge: www.pacificedgedx.com Pacific Edge Limited (NZX/ ASX:…”